We use data from PubMed and other sources to examine the impact of public and private research support on premature (before ages 75, 65, and 55) cancer mortality and hospitalization, by estimating difference-in-differences models based on longitudinal, cancer-site-level data on about 30 cancer sites.
I. Introduction
In a previous study, Lichtenberg (2013) used PubMed 1 data on the number of publications about different types of cancer (breast, colon, lung, etc.) to provide evidence about the impact of biomedical research on U.S. cancer mortality rates. 2 Estimates from that study indicated that mortality rates: (1) are unrelated to the (current or lagged) stock of publications that had not received research funding;
(2) are only weakly inversely related to the contemporaneous stock of published articles that received research funding; and (3) are strongly inversely related to the stock of articles that had received research funding and been published 5 and 10 years earlier.
In this paper, we will extend and update the analysis performed in Lichtenberg (2013) in a number of important respects:
• The sole outcome measure analyzed in the previous study was the age-adjusted mortality rate. In this paper, we will analyze a different type of mortality measure: years of potential life lost (YPLL) before three ages (75, 65, and 55) . 3 Estimates of YPLL models (but not of age-adjusted mortality rate models) enable us to calculate the number of lifeyears gained from biomedical research.
• In addition to analyzing the impact of biomedical research on premature cancer mortality, we will analyze its effect on hospitalization (the number of inpatient hospital discharges and days of care) due to cancer. Hospital care was the largest single component of U.S. medical expenditure in 2014, accounting for 32% of total expenditure (Centers for
Medicare & Medicaid Services (2017)). 1 PubMed comprises over 26 million citations for biomedical literature from MEDLINE, life science journals, and online books. PubMed citations and abstracts include the fields of biomedicine and health, covering portions of the life sciences, behavioral sciences, chemical sciences, and bioengineering. PubMed also provides access to additional relevant web sites and links to the other NCBI molecular biology resources. PubMed is a free resource that is developed and maintained by the National Center for Biotechnology Information (NCBI), at the U.S. National Library of Medicine (NLM), located at the National Institutes of Health (NIH). 2 Previous research on the agricultural (Evenson and Kislev (1973) ) and manufacturing (Adams (1990) ) sectors of the economy had found that counts of publications are useful indicators of the stock of knowledge. 3 Previous authors have argued that "reducing premature mortality is a crucial public health objective" (Renard, Tafforeau, and Deboosere (2014) ). A widely used measure of premature mortality is years of potential life lost (YPLL) before a given age (e.g. age 75), i.e. the number of years not lived by an individual who died before that age (Association of Public Health Epidemiologists in Ontario (2015)). Statistics of YPLL are published by the World Health Organization, the OECD, and government agencies of the U.S., Switzerland, and other countries. Burnet et al (2005) argue that YPLL "should be considered when allocating research funds."
• The previous study controlled for changes in incidence by including just the contemporaneous age-adjusted incidence rate (in year t) in the age-adjusted mortality model. In this paper, we will control for the average annual number of patients diagnosed in years t-9 to t in the premature mortality and hospitalization models.
• In the previous study, all publications in which a specific type of cancer was a topic were included. In this paper, only publications in which a specific type of cancer was one of the main topics are included. 4
• In the previous study, the maximum allowed lag from publication to mortality was 10 years. In this paper, we allow for lags of up to 24 years.
• The functional form specified in the previous study was log-log. In this paper, we will estimate semi-logarithmic models. Comparison of the marginal effects of research-based and non-research-based publications is more straightforward in the semi-logarithmic model.
• In the previous study, the sample period was 1995-2009. This paper will analyze a more recent period: 1999-2013.
In the next section of this paper, we describe the econometric model of premature mortality and hospitalization that we will estimate. In Section III, we describe the data sources we rely upon to construct the dataset used to estimate the model and present descriptive statistics; all of the data are publicly available. Estimates of the models are presented in Section IV. Implications of the estimates are discussed in Section V. Section VI contains a summary and conclusions.
II. Econometric model of premature mortality and hospitalization
To assess the impact of biomedical research on premature cancer mortality and hospitalization, I will estimate the following difference-in-differences model based on CUM_OTHER_PUBSs,t-k = the number of PubMed articles published by the end of year t-k that had cancer at site s as a "main topic" and that did not mention either U.S. Government or non-U.S. Government research support CASES_10_YEARSst = the average annual number of patients diagnosed with cancer at site s in SEER 9 registries in years t-9 to t αs = a fixed effect for cancer at site s δt = a fixed effect for year t 5 Disentangling the effects of U.S. Government and non-U.S. Government research support is difficult. As shown in Lichtenberg (2013) , almost half of the publications that cite U.S. Government research support also cite non-U.S. Government research support. Non-U.S. government financial support includes support by American societies, institutes, state governments, universities, and private organizations, and by foreign sources (national, departmental, provincial, academic & private organizations).
εst = a disturbance
The fixed year effects control for time-varying factors that influence cancer mortality and hospitalization in general. The models will be estimated by weighted least squares, weighting by
(1 / 15) ΣtYst. Disturbances will be clustered within cancer sites.
III. Data sources and descriptive statistics
Premature mortality data. Data on the number of years of potential life lost before ages 75, 65, and 55, by cancer site and year, were constructed from data contained in the WHO Mortality Database. Data for 1999 and 2013 are shown in Table 1 . Figure 1 shows data on the number of years of potential life lost before age 75 in 1999 and 2013 for 4 cancer sites that had roughly similar numbers (between 141 and 196 thousand) of YPLL75 in 1999. The 1999-2013 change in YPLL75 varied considerably across these 4 cancer sites.
Hospitalization data. Data on the number of inpatient hospital discharges and days of care, by cancer site and year, were constructed from data contained in the Healthcare Cost and Utilization Project (Agency for Healthcare Research and Quality (2017)). The number of days of care was computed as the number of discharges times average length of stay. Data for 1999 and 2013 are shown in Table 2 .
Research-based and other publications. Data on CUM_RESEARCH_PUBS and CUM_OTHER_PUBS, by cancer site and year, were constructed by performing searches on the PubMed Advanced Search Builder. As shown in Appendix Incidence data. Data on the number of people diagnosed in SEER 9 registries, by cancer site and
year, were obtained from the National Cancer Institute's SEER*Stat Software. Data for 1999
and 2013 are shown in Table 4 .
IV. Empirical results
Estimates of parameters of premature mortality models (eq. (1), where Y = YPLL75, YPLL65, or YPLL55) are shown in In lines 1-9, the dependent variable is ln(YPLL75), and k = 0, 3, 6, …, 24, respectively.
As shown in lines 1-3, βresearch is negative but not statistically significant when k < 6. However, as shown in lines 4-6, βresearch is negative and statistically significant (p-value < .05) when 9 < k < 15. This indicates that premature (before age 75) mortality is inversely related to the number of research-supported articles that had been published 9-15 years earlier, controlling for the number of other articles that had been published 9-15 years earlier and for the average annual number of patients diagnosed in SEER 9 registries in the previous 10 years. The estimate in line 5 implies that 1000 additional research-supported publications is associated with a 1.3%
YPLL75 reduction 12 years later. The point estimates of βresearch when 18 < k < 24 are similar to the point estimates when 9 < k < 15, but the standard errors are much larger when 18 < k < 24, so those estimates are not statistically significant. 6 The estimates of βresearch for 0 < k < 24 from ln(YPLL75) models are shown (on an inverted scale) in Figure 3 .
None of the estimates of βother in lines 1-9 are statistically significant: premature (before age 75) mortality is unrelated to the number of publications that did not mention either U.S.
Government or non-U.S. Government research support. All of the estimates of γ in lines 1-9 are statistically significant: YPLL75 is significantly positively related to the number of people diagnosed in the previous 10 years.
In lines 10-18 of Table 5 , the dependent variable is ln(YPLL65). These estimates are quite similar to the estimates in lines 1-9. PYLL65 is inversely related to the number of research-supported articles that had been published 12-15 years earlier, and is unrelated to the number of other articles. It is also unrelated to the number of people diagnosed in the previous 10 years, presumably because about half of cancer patients are diagnosed after the age of 65. 7
In lines 19-27 of Table 5 , the dependent variable is ln(YPLL55). The estimates of βresearch for 0 < k < 24 from ln(YPLL55) models are shown in Figure 4 . The point estimates of βresearch are strictly increasing with respect to lag length. The estimates for 0 < k < 15 are not statistically significant, but the estimates for 18 < k < 24 are statistically significant. This indicates that the number of years of potential life lost before age 55 is inversely related to the number of research-supported articles that had been published 18-24 years earlier, and that 1000 additional research-supported publications is associated with a 4.2% YPLL55 reduction 24 years later. Evidently, the lag from research-supported publications to premature mortality reduction is considerably longer for YPLL55 than it is for YPLL75.
Estimates of parameters of hospitalization models (eq. (1), where Y = DISCHARGES or HOSP_DAYS) are shown in Table 6 . In lines 1-9, the dependent variable is ln(DISCHARGES).
The estimates of βresearch for 0 < k < 24 from ln(DISCHARGES) models are shown in Figure 5 .
For all values of k, the estimate is negative and statistically significant. Once again, the point estimates of βresearch are strictly increasing with respect to lag length. The estimate of βresearch in line 9 of Table 6 indicates that 1000 additional research-supported publications is associated with a 10% DISCHARGES reduction 24 years later. The estimates in lines 1-9 indicate that the number of hospital discharges is significantly positively related to the number of people diagnosed in the previous 10 years, as expected. The estimates also indicate that the number of hospital discharges is also significantly positively related to the number of other (non-researchsupported) publications, which is somewhat surprising. However, the magnitudes of the βother coefficients are much smaller than the magnitudes of the βresearch coefficients: the estimate of 7 https://www.cancer.gov/about-cancer/causes-prevention/risk/age βother in line 9 indicates that 1000 additional non-research-supported publications is associated with only a 1.6% DISCHARGES increase 24 years later.
In lines 10-18, the dependent variable is ln(HOSP_DAYS). Estimates of the parameters of HOSP_DAYS models are quite similar to estimates of the parameters of DISCHARGES models.
V. Discussion
The estimates of eq. (1) indicate that cancer sites about which more research-supported articles were published since the 1970s had larger reductions in premature mortality and hospitalization during the period 1999-2013, controlling for the change in the number of people diagnosed. Cancer sites for which more non-research-supported articles were published did not have larger reductions in premature mortality or hospitalization.
We can use the estimates to calculate the reduction in premature mortality in 2013 attributable to previous publication of research-supported articles. Lines 1-9 of higher.
VI. Summary and conclusions
A previous study used PubMed data on the number of publications about different types of cancer (breast, colon, lung, etc.) to provide evidence about the impact of biomedical research on U.S. cancer mortality rates. In this paper, we extended and updated the analysis performed in the earlier study in several important respects: we analyzed a different type of mortality measure (years of potential life lost (YPLL) before three ages (75, 65, and 55)); we analyzed the effect of research-supported publications on hospitalization as well as on mortality; we controlled for lagged as well as current cancer incidence; and we allowed for longer (24 years vs. 10 years) lags from publication to cancer outcomes.
To assess the impact of biomedical research on premature cancer mortality and hospitalization, we estimated difference-in-differences models based on longitudinal, cancer-sitelevel data on about 30 cancer sites. The estimates indicated that cancer sites about which more research-supported articles were published since the 1970s had larger reductions in premature mortality and hospitalization during the period 1999-2013, controlling for the change in the number of people diagnosed. Cancer sites for which more non-research-supported articles were published did not have larger reductions in premature mortality or hospitalization.
Premature (before age 75) mortality is inversely related to the number of researchsupported articles that had been published 9-15 years earlier, controlling for the number of other articles that had been published 9-15 years earlier and for the average annual number of patients diagnosed in SEER 9 registries in the previous 10 years. The estimates indicated that 1000 additional research-supported publications is associated with a 1.3% YPLL75 reduction 12 years later. Estimates of models of YPLL65 were quite similar to estimates of models of YPLL75.
YPLL65 is inversely related to the number of research-supported articles that had been published 12-15 years earlier, and is unrelated to the number of other articles.
The number of years of potential life lost before age 55 is inversely related to the number of research-supported articles that had been published 18-24 years earlier; 1000 additional research-supported publications is associated with a 4.2% YPLL55 reduction 24 years later.
Evidently, the lag from research-supported publications to premature mortality reduction is considerably longer for YPLL55 than it is for YPLL75.
The number of hospital discharges attributed to cancer is significantly inversely related to the number of research-supported articles at every lag length investigated (from 0 to 24 years), but the magnitude of the effect is strictly increasing with respect to lag length. The estimates indicated that 1000 additional research-supported publications is associated with a 10% reduction in hospital discharges 24 years later. Table 5 Estimates of premature mortality model parameters from eq. (1): Note: estimates in bold are statistically significant (p-value < .05). The models were estimated by weighted least squares, weighting by (1 / 15) Σ t Y st . Disturbances were clustered within cancer sites. 
Y = DISCHARGES Y = HOSP_DAYS

